news
Low-Dose Rapamycin Restores Brain Blood Flow in APOE4 Carriers
A four-week trial found low-dose rapamycin significantly boosted cerebral blood flow in healthy middle-aged adults carrying the high-risk APOE4 gene variant. Women showed the strongest vascular response, providing rare human clinical evidence that targeting cellular senescence can improve brain perfusion decades before cognitive symptoms appear.
A four-week trial found low-dose rapamycin significantly boosted cerebral blood flow in healthy middle-aged adults carrying the high-risk APOE4 gene variant. Women showed the strongest vascular response, providing rare human clinical evidence that targeting cellular senescence can improve brain perfusion decades before cognitive symptoms appear.
The architecture take
Longevity medicine talks endlessly about rapamycin, but most data doesn't leave mouse cages. I spent years tuning out the biohacking chatter because cycling an immunosuppressant without human proof seemed reckless. This trial shifts my calculus. Four weeks of low dosing dialed up cerebral perfusion in APOE4 carriers, with female brains responding fastest. I track mTOR because dampening it clears cellular debris, dials down vascular inflammation, and lets cerebral microvessels relax enough to deliver glucose. Alzheimer's doesn't start with sudden memory loss; it starts as decades of quiet vascular starvation. Women get hit hardest because perimenopausal shifts already destabilize brain energy use (estrogen drops hit cerebral metabolism early). I'm still not rushing out to buy off-label sirolimus from a longevity clinic tomorrow. Rapamycin carries real immune trade-offs that demand disciplined dosing. But seeing human microvascular flow rebound in one month gives me an actual clinical marker to watch.